Pioneering first-in-class HDAC-ROCK inhibitors as potential multitarget anticancer agents.

Beljkas M, Ruzic D, Djuric A, Vuletic A, Tchiehe GN, Jallet C, Cadet-Daniel V, Arimondo PB, Santibanez JF, Srdic-Rajic T, Nikolic K, Oljacic S, Petkovic M

Open source

DOI: 10.1080/17568919.2025.2459589
Published: 2025 Feb
Container: Future medicinal chemistry
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/17568919.2025.2459589,
  title = {Pioneering first-in-class HDAC-ROCK inhibitors as potential multitarget anticancer agents.},
  author = {Beljkas M and Ruzic D and Djuric A and Vuletic A and Tchiehe GN and Jallet C and Cadet-Daniel V and Arimondo PB and Santibanez JF and Srdic-Rajic T and Nikolic K and Oljacic S and Petkovic M},
  year = {2025},
  journal = {Future medicinal chemistry},
  doi = {10.1080/17568919.2025.2459589},
  url = {https://doi.org/10.1080/17568919.2025.2459589}
}

RIS

TY  - JOUR
TI  - Pioneering first-in-class HDAC-ROCK inhibitors as potential multitarget anticancer agents.
AU  - Beljkas M
AU  - Ruzic D
AU  - Djuric A
AU  - Vuletic A
AU  - Tchiehe GN
AU  - Jallet C
AU  - Cadet-Daniel V
AU  - Arimondo PB
AU  - Santibanez JF
AU  - Srdic-Rajic T
AU  - Nikolic K
AU  - Oljacic S
AU  - Petkovic M
PY  - 2025
JO  - Future medicinal chemistry
DO  - 10.1080/17568919.2025.2459589
UR  - https://doi.org/10.1080/17568919.2025.2459589
ER  -

APA

M, B., D, R., A, D., A, V., GN, T., C, J., V, C., PB, A., JF, S., T, S., K, N., S, O., & M, P. (2025). Pioneering first-in-class HDAC-ROCK inhibitors as potential multitarget anticancer agents.. Future medicinal chemistry. https://doi.org/10.1080/17568919.2025.2459589

Source records

pubmed · retrieved 2026-09-25T22:54:45.015Z